Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

Video

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

There are many drugs approved for patients with metastatic urothelial cancer. The highest levels of evidence are with pembrolizumab (Keytruda) and atezolizumab (Tecentriq) based on phase III data to support both regimens. Determining the sequencing of these agents remains a challenge to be investigated, according to Pal.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,